We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 304.00
Bid: 301.00
Ask: 304.00
Change: 14.00 (4.83%)
Spread: 3.00 (0.997%)
Open: 310.00
High: 314.00
Low: 304.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chi-Med to Attend Upcoming Investor Conferences

11 May 2020 07:00

RNS Number : 3486M
Hutchison China Meditech Limited
11 May 2020
 

Press Release

Chi-Med to Attend Upcoming Investor Conferences

London: Friday, May 11, 2020: Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) today announces that Mr Christian Hogg, Chief Executive Officer of Chi-Med, will participate in a virtual fireside chat at the Bank of America 2020 Health Care Conference on Thursday, May 14, 2020 9:40 a.m. Eastern Daylight Time (EDT).

 

The discussion will be webcast live and can be accessed at www.chi-med.com in the Shareholder Information section under "Events, Circulars & Forms." Investors interested in listening to the live webcast should log on before the start time to download any software required. A replay of the event will be available shortly thereafter for approximately 90 days.

 

Members of the senior management team will also attend virtual one-on-one meetings at the Bank of America Health Care Conference on May 14, as well as during the following other conferences:

 

· Citi Virtual Pan-Asia Regional Investor Conference from Tuesday to Thursday, May 19 to 21, 2020;

 

· Jefferies Virtual Global Healthcare Conference from Tuesday to Thursday, June 2 to 4, 2020; and

 

· Goldman Sachs Global Healthcare Conference Webcast from Tuesday to Thursday, June 9 to 11, 2020.

 

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

 

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

 

CONTACTS

Investor Enquiries

Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President

+1 (973) 567 3786

Media Enquiries

 

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile) bmiles@troutgroup.com

Europe - Ben Atwell / Alex Shaw, FTI Consulting

+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)Chi-Med@fticonsulting.com

Asia - Joseph Chi Lo / Zhou Yi, Brunswick

+852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 9783 6894 (Mobile), yzhou@brunswickgroup.com

Nominated Advisor

Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMZGGKRRZGGZG
Date   Source Headline
29th Mar 20168:00 amRNSDirector/PDMR Shareholding
23rd Mar 201610:34 amRNSHolding(s) in Company
22nd Mar 20162:00 pmRNSClosing of U.S. Public Offering of ADSs
21st Mar 20168:54 amRNSDirector/PDMR Shareholding
21st Mar 20167:00 amRNSSulfatinib Phase III registration study
18th Mar 20164:18 pmRNSFinal Prospectus
17th Mar 20167:00 amRNSPricing of U.S. Public Offering of ADSs
15th Mar 20167:00 amRNS2015 Annual Report and Notice of AGM
7th Mar 20167:59 amRNSFifth Filing of Form F-1 Registration Statement
4th Mar 20166:12 pmRNSLaunch of Potential U.S. Public Offering of ADSs
4th Mar 20165:54 pmRNSFifth Filing of Form F-1 Registration Statement
2nd Mar 20167:00 amRNSSulfatinib Phase II initation in thyroid cancer
1st Mar 20164:29 pmRNSFourth Filing of Form F-1 Registration Statement
1st Mar 20167:00 amRNSFinal Results
11th Feb 20165:39 pmRNSPublic Filing of Form F-1 Registration Statement
29th Jan 20168:03 amRNSNotice of Results
15th Jan 20167:02 amRNSChi-Med initiates HMPL-523 Phase I clinical trial
29th Dec 20157:43 amRNSBlocklisting Six Monthly Return
18th Dec 20157:00 amRNSInitiation sulfatinib Phase III registration study
9th Dec 20157:00 amRNSUS$105 m Shanghai land compensation agreement
8th Dec 20157:00 amRNSInitiation of fruquintinib Phase 3 trial in NSCLC
13th Nov 20152:50 pmRNSSecond Public Filing of Registration Statement
10th Nov 20151:13 pmRNSResults of Extraordinary General Meeting
9th Nov 20157:59 amRNSDirector/PDMR Shareholding
6th Nov 20157:00 amRNSChi-Med initiates sulfatinib U.S. clinical trials
30th Oct 20157:00 amRNSClinical results presented
30th Oct 20157:00 amRNSTotal Voting Rights
30th Oct 20157:00 amRNSCompletion of Phase I clinical trial of HMPL 523
20th Oct 20152:40 pmRNSDirector's Share Dealing
19th Oct 20157:00 amRNSAwards under Long Term Incentive Plan
16th Oct 201512:17 pmRNSShareholders' Circular and Notice of EGM
16th Oct 201512:15 pmRNSFiling of Registration Statement on Form F1
16th Oct 201512:03 pmRNSChi-Med files Nasdaq Registration Statement
13th Oct 20157:00 amRNSEnrolment complete in Savolitinib Phase II trial
12th Oct 20152:09 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSPresentation at 2015 European Cancer Congress
2nd Sep 201511:57 amRNSTrial of fruquintinib achieves primary endpoint
19th Aug 201512:14 pmRNSTermination of R&D agreement with Janssen
28th Jul 20157:00 amRNSInterim Results
23rd Jul 20151:05 pmRNSNotification of major interest in shares
23rd Jul 20151:01 pmRNSNotification of major interest in shares
23rd Jul 20159:01 amRNSMitsui exchanges shares in Hutchison MediPharma
17th Jul 20157:00 amRNSInvention patent granted for SXBXP
6th Jul 20157:00 amRNSNotice of Announcement of 2015 Interim Results
29th Jun 20157:00 amRNSBlocklisting Six Monthly Return
1st Jun 20157:00 amRNSSavolitinib preliminary Phase Ib data presented
13th May 20157:00 amRNSFruquintinib results trigger payments from Lilly
30th Apr 20157:00 amRNSTotal Voting Rights
24th Apr 201512:40 pmRNSResult of AGM
22nd Apr 201511:23 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.